RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:458763

Retiform hemangioendothelioma

medium confidenceDisorder

Publications

220

69.3th percentile

Trials

0

Interventional, condition-specific

Researchers

882

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare vascular tumor characterized by a slowly growing lesion with predominant involvement of the skin and subcutaneous tissue of the distal extremities. Distinctive arborizing blood vessels lined by endothelial cells with characteristic hobnail morphology are a typical feature. Local recurrences are frequent unless wide local excision is performed, while metastasis is rare.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

hobnail hemangioendothelioma · retiform hemangioendothelioma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    220 matched papers (119 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 24 for broader category hemangioendothelioma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

220

220 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

220 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

119 in the last 10 years · medium confidence · 69.3th percentile (publications denominator)

Phrase hits: 220 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

882

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Antonescu CR6 papers · 2024

    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

    Papers in Europe PMC
  2. 02
    Díaz-Flores L6 papers · 2024

    Department of Physical Medicine and Pharmacology, Faculty of Medicine, University of La Laguna, Tenerife, Spain.

    Papers in Europe PMC
  3. 03
    Miettinen M5 papers · 2012

    Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. miettinen@afip.osd.mil

    Papers in Europe PMC
  4. 04
    Wang ZF4 papers · 2012
    Papers in Europe PMC
  5. 05
    Calonje E3 papers · 2011

    Soft Tissue Tumour Unit, St. Thomas's Hospital, London, England.

    Papers in Europe PMC
  6. 06
    Dermawan JK3 papers · 2024

    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

    Papers in Europe PMC
  7. 07
    Fletcher CD3 papers · 1999

    Department of Pathology, Harvard Medical School, Boston, MA, USA.

    Papers in Europe PMC
  8. 08
    Gutiérrez R3 papers · 2024

    Department of Basic Medical Sciences, Faculty of Medicine, University of La Laguna, Tenerife, Spain.

    Papers in Europe PMC
  9. 09
    Kutzner H3 papers · 2013
    Papers in Europe PMC
  10. 10
    Madrid JF3 papers · 2024

    Department of Cell Biology and Histology, School of Medicine, Campus of International Excellence, "Campus Mare Nostrum", IMIB-Arrixaca, University of Murcia, Murcia, Spain.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 24 trials are registered for hemangioendothelioma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

24 interventional trials matched hemangioendothelioma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: hemangioendothelioma

24

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Retiform hemangioendothelioma" OR "hobnail hemangioendothelioma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Retiform hemangioendothelioma" OR "hobnail hemangioendothelioma"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"hemangioendothelioma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (220) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T16:52:18.866Z